カテゴリ： GlobalData, アメリカ, 企業調査

Seattle Genetics Inc (SGEN)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Seattle Genetics Inc (SGEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8012259
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月14日
◆ページ数：110
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Seattle Genetics Inc (Seattle Genetics) is a biotechnology company that develops and commercializes monoclonal antibody-based therapies for the treatment of cancer. The company’s lead product Adcetris (brentuximab vedotin) is an antibody-drug conjugate indicated for the treatment of relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics’ product pipeline consists of SGN-CD33A (vadastuximab talirine) for acute myeloid leukemia (AML) and myelodysplastic syndrome; and ASG-22ME (enfortumab vedotin) for metastatic urothelial cancer. Its pipeline also comprises six antibody-drug conjugate (ADC) programs and two immuno-oncology programs in various clinical stages of development. It uses ADC and sugar-engineered antibody (SEA) technologies for the development of its product portfolio. The company sells its products through pharmaceutical distributors and collaborators. Seattle Genetics is headquartered in Bothell, Washington, the US.

Seattle Genetics Inc (SGEN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Seattle Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Seattle Genetics Inc, Medical Devices Deals, 2011 to YTD 2017 11
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Seattle Genetics to Acquire Pharma Manufacturing Facility from Bristol-Myers Squibb 14
Venture Financing 15
Unum Therapeutics Raises USD65 Million in Series B Financing 15
Partnerships 17
Seattle Genetics Enters into Clinical Agreements for SGN-LIV1A 17
Genmab Exercises Option for Licensing Agreement with Seattle Genetics 18
Seattle Genetics Enters into Agreement with Genentech 19
Seattle Genetics and Bristol-Myers Squibb Enter into Clinical Trial Agreement 20
Bristol-Myers Squibb and Seattle Genetics Enter into Agreement 21
Genmab Enters into Research Agreement with Seattle Genetics 22
Seattle Genetics Expands Co-Development Agreement With AbbVie 23
Seattle Genetics Exercises Option For Co-Development Agreement With Agensys For ASG-15ME 25
Seattle Genetics Enters Into Co-Development Agreement With Oxford BioTherapeutics 26
Seattle Genetics Exercises Its Option Co-Development Agreement With Agensys 27
Genmab Enters Into Research Collaboration With Seattle Genetics 28
Seattle Genetics Enters Into Collaboration With Abbott 29
Licensing Agreements 30
AbbVie Enters into Licensing Agreement with Life Science Pharma and Seattle Genetics 30
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 31
Seattle Genetics Enters into Licensing Agreement with Unum Therapeutics 32
Bayer HealthCare Enters Into Licensing Agreement With Seattle Genetics 33
Seattle Genetics Extends Licensing Agreement With Millennium 34
Seattle Genetics Enters Into Licensing Agreement With Pfizer 35
Equity Offering 36
Seattle Genetics Announces Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 36
Unum Therapeutics Plans to Raise USD5 Million in Private Placement of Shares 38
Seattle Genetics Completes Private Placement Of Shares For US$9 Million 39
Seattle Genetics Announces Exercise Of Underwriters Over-Allotment Option For US$178 Million 40
Acquisition 42
Seattle Genetics Acquires 2.8% Stake in Immunomedics 42
Seattle Genetics Inc – Key Competitors 44
Seattle Genetics Inc – Key Employees 45
Seattle Genetics Inc – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Recent Developments 47
Financial Announcements 47
Oct 26, 2017: Seattle Genetics Reports Third Quarter 2017 Financial Results 47
Jul 27, 2017: Seattle Genetics Reports Second Quarter 2017 Financial Results 49
Apr 27, 2017: Seattle Genetics Reports First Quarter 2017 Financial Results 51
Feb 09, 2017: Seattle Genetics Reports Fourth Quarter and Year 2016 Financial Results 53
Oct 27, 2016: Seattle Genetics Reports Third Quarter 2016 Financial Results 55
Jul 26, 2016: Seattle Genetics Reports Second Quarter 2016 Financial Results 57
Apr 28, 2016: Seattle Genetics Reports First Quarter 2016 Financial Results 59
Feb 09, 2016: Seattle Genetics Reports Fourth Quarter and Year 2015 Financial Results 61
Corporate Communications 63
Oct 04, 2016: Seattle Genetics Announces Executive Promotions and Leadership Appointment 63
Product News 64
12/05/2016: Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS (Brentuximab Vedotin) in Combination with Opdivo (nivolumab) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting 64
11/10/2016: Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS (Brentuximab Vedotin) in Mycosis Fungoides and Primary Cutaneous Anaplastic Large Cell Lymphoma 66
11/03/2016: Seattle Genetics Announce data on Denintuzumab Mafodotin at ASH 2016 68
10/20/2016: Seattle Genetics Demonstrates Commitment to Improve Hodgkin Lymphoma Treatment Paradigm through Multiple ADCETRIS (Brentuximab Vedotin) Data Presentations at ISHL 2016 69
10/18/2016: Takeda Showcases Continued Commitment in Hodgkin Lymphoma During 10th International Symposium on Hodgkin Lymphoma 71
05/27/2016: Takeda Receives Positive CHMP Opinion for ADCETRIS (brentuximab vedotin) as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma 72
Mar 30, 2017: Seattle Genetics Highlights Leadership in Antibody-Drug Conjugate Technology Innovation at the American Association for Cancer Research (AACR) Annual Meeting 73
01/21/2017: Johnson & Weaver Announces Filing of Class Action Complaint Against Seattle Genetics Encourages all Investors to Contact the Firm for Information 75
Product Approvals 76
Jul 06, 2016: Takeda Receives European Commission Approval of ADCETRIS (brentuximab vedotin) for Consolidation Treatment in Post-Transplant Hodgkin Lymphoma 76
Jan 22, 2016: European Commission Approves Label Variation for ADCETRIS to Include Data on Retreatment of Adult Patients with Relapsed or Refractory Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma 77
Clinical Trials 78
Dec 07, 2017: Seattle Genetics Presents Updated Phase 1 Data for Ladiratuzumab Vedotin (SGN-LIV1A) in Patients with Triple Negative Breast Cancer at 2017 San Antonio Breast Cancer Symposium 78
Mar 06, 2017: FDA Lifts Clinical Hold on Seattle Genetics’ Phase 1 Trials of Vadastuximab Talirine 80
Dec 27, 2016: Seattle Genetics Announces Clinical Hold on Several Phase 1 Trials of Vadastuximab Talirine (SGN-CD33A) 81
Dec 10, 2016: Seattle Genetics Highlights Phase 1 Data for Novel Antibody-Drug Conjugate SGN-LIV1A in Patients with Metastatic Breast Cancer at San Antonio Breast Cancer Symposium 82
Dec 05, 2016: Seattle Genetics Highlights Long-Term Follow-Up Data from ADCETRIS (Brentuximab Vedotin) in T-Cell Lymphomas at ASH Annual Meeting 83
Dec 05, 2016: Seattle Genetics Highlights Phase 1 Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations, Including Combination Therapy with HMAs, in Patients with Acute Myeloid Leukemia at ASH Annual Meeting 85
Dec 03, 2016: Seattle Genetics Presents Phase 1b Data from Vadastuximab Talirine (SGN-CD33A; 33A) in Combination with Standard of Care in Frontline Acute Myeloid Leukemia at ASH Annual Meeting 87
Dec 03, 2016: Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma 89
Nov 08, 2016: Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS (Brentuximab Vedotin) in Frontline Mature T-cell Lymphoma 92
Nov 03, 2016: Seattle Genetics Announces ASH 2016 Abstracts Highlighting Data on ADCETRIS (brentuximab vedotin) Development Programs 94
Nov 03, 2016: Seattle Genetics Announces ASH 2016 Abstracts Highlighting Data on vadastuximab talirine (SGN-CD33A) Development Programs 96
Nov 03, 2016: Takeda to Present Clinical Data on ADCETRIS (brentuximab vedotin) During 58th American Society of Hematology Annual Meeting 98
Aug 01, 2016: Takeda and Seattle Genetics Announce Positive Data from Phase 3 ALCANZA Clinical Trial of ADCETRIS (Brentuximab Vedotin) for CD30-Expressing Cutaneous T-Cell Lymphoma 99
Jul 18, 2016: Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood 101
Jul 18, 2016: Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood 103
Jun 11, 2016: Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association 105
Apr 18, 2016: Seattle Genetics Highlights Data on SGN-LIV1A at the American Association for Cancer Research Annual Meeting 107
Apr 18, 2016: Seattle Genetics Highlights Data on 2-fluorofucose (2FF) at the American Association for Cancer Research Annual Meeting 108
Apr 18, 2016: Seattle Genetics Highlights Data on ADCETRIS at the American Association for Cancer Research Annual Meeting 109
Appendix 110
Methodology 110
About GlobalData 110
Contact Us 110
Disclaimer 110

List of Tables
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Seattle Genetics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Seattle Genetics Inc, Deals By Therapy Area, 2011 to YTD 2017 10
Seattle Genetics Inc, Medical Devices Deals, 2011 to YTD 2017 11
Seattle Genetics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Seattle Genetics to Acquire Pharma Manufacturing Facility from Bristol-Myers Squibb 14
Unum Therapeutics Raises USD65 Million in Series B Financing 15
Seattle Genetics Enters into Clinical Agreements for SGN-LIV1A 17
Genmab Exercises Option for Licensing Agreement with Seattle Genetics 18
Seattle Genetics Enters into Agreement with Genentech 19
Seattle Genetics and Bristol-Myers Squibb Enter into Clinical Trial Agreement 20
Bristol-Myers Squibb and Seattle Genetics Enter into Agreement 21
Genmab Enters into Research Agreement with Seattle Genetics 22
Seattle Genetics Expands Co-Development Agreement With AbbVie 23
Seattle Genetics Exercises Option For Co-Development Agreement With Agensys For ASG-15ME 25
Seattle Genetics Enters Into Co-Development Agreement With Oxford BioTherapeutics 26
Seattle Genetics Exercises Its Option Co-Development Agreement With Agensys 27
Genmab Enters Into Research Collaboration With Seattle Genetics 28
Seattle Genetics Enters Into Collaboration With Abbott 29
AbbVie Enters into Licensing Agreement with Life Science Pharma and Seattle Genetics 30
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 31
Seattle Genetics Enters into Licensing Agreement with Unum Therapeutics 32
Bayer HealthCare Enters Into Licensing Agreement With Seattle Genetics 33
Seattle Genetics Extends Licensing Agreement With Millennium 34
Seattle Genetics Enters Into Licensing Agreement With Pfizer 35
Seattle Genetics Announces Underwriters Exercise of Over-Allotment Option of Public Offering of Shares 36
Unum Therapeutics Plans to Raise USD5 Million in Private Placement of Shares 38
Seattle Genetics Completes Private Placement Of Shares For US$9 Million 39
Seattle Genetics Announces Exercise Of Underwriters Over-Allotment Option For US$178 Million 40
Seattle Genetics Acquires 2.8% Stake in Immunomedics 42
Seattle Genetics Inc, Key Competitors 44
Seattle Genetics Inc, Key Employees 45
Seattle Genetics Inc, Subsidiaries 46

★海外企業調査レポート[Seattle Genetics Inc (SGEN)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Zenosense Inc (ZENO)：医療機器：M&Aディール及び事業提携情報
    Summary Zenosense Inc (Zenosense) is a medical device company that develops transformational medical diagnostic technologies. The company develops MIDS Cardiac, a hand held cardiac diagnostic device that applies patent-protected magnetic nanoparticle detection technology used for the rapid testing o …
  • Alfresa Holdings Corp (2784)：企業の財務・戦略的SWOT分析
    Summary Alfresa Holdings Corp (Alfresa) is a wholesale distributor and manufacturer of pharmaceuticals products. The company is engaged in ethical pharmaceuticals wholesaling business which delivers a wide range of products, including diagnostic reagents and medical devices. It delivers self medicat …
  • Fibra Uno Administracion, S. A. De C. V.
    Fibra Uno Administracion, S. A. De C. V. - Strategy, SWOT and Corporate Finance Report Summary Fibra Uno Administracion, S. A. De C. V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Senvion SA：電力：M&Aディール及び事業提携情報
    Summary Senvion S.A. (Senvion) formerly Senvion S.a.r.l, is a renewable energy company that develops, produces and distributes onshore and offshore wind turbines and towers. It also offers project specific solutions such as turnkey, foundation construction, transport and installation, and service an …
  • Align Technology, Inc.：戦略・SWOT・企業財務分析
    Align Technology, Inc. - Strategy, SWOT and Corporate Finance Report Summary Align Technology, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • BioView Ltd (BIOV)：企業の財務・戦略的SWOT分析
    BioView Ltd (BIOV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • China CAMC Engineering Co Ltd (002051)：企業の財務・戦略的SWOT分析
    Summary China CAMC Engineering Co Ltd (CAMC), a subsidiary of China National Machinery Industry Corp, is a construction company that offers engineering, procurement and construction services. The company designs and constructs shipyard, turnkey project in pulp plant, agricultural equipment industria …
  • Mycenax Biotech Inc (4726)：製薬・医療：M&Aディール及び事業提携情報
    Summary Mycenax Biotech Inc (Mycenax) is a biopharmaceutical company that develops and manufactures pharmaceutical formulations. The company provides pipeline portfolio encompasses investigational candidates targeted at the treatment of plaque psoriasis, glioblastoma, asthma, adult crohn's Disease, …
  • Australian Gas Networks Ltd：電力：M&Aディール及び事業提携情報
    Summary Australian Gas Networks Ltd (Australian Gas Networks), formerly Envestra Ltd is an oil and gas company that distributes and transports natural gas. The company's services include managing the haulage of gas through each network, operation and maintenance of gas network, design an constructio …
  • TMX Group Limited (X)：企業の財務・戦略的SWOT分析
    TMX Group Limited (X) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • TAS Energy Inc-エネルギー分野：企業M&A・提携分析
    Summary TAS Energy, Inc. (TAS), formerly Turbine Air Systems, Ltd., offers clean and modular energy solutions. The company designs, manufactures and supplies turbine inlet chilling systems for power augmentation; modular utility systems for air cooling; waste heat/geothermal systems for power genera …
  • Avacta Group Plc (AVCT)：製品パイプライン分析
    Summary Avacta Group Plc (Avacta) is a developer therapeutic molecules used in a wide range of life sciences applications in research and diagnostics. The company offers products which include optim and sensipod. It also develops UCB celltech, which is an analytical instrument. Avacta’s sensipod is …
  • Sulzer Ltd (SUN)-エネルギー分野：企業M&A・提携分析
    Summary Sulzer Ltd (Sulzer) is an industrial engineering company that manufactures and supplies pump equipment. It offers mixers, compressors, agitators and aeration equipment. The company provides repair and maintenance service solutions for turbines, pumps, compressors, motors, and generators. Sul …
  • Gold Fields Ltd：戦略・SWOT・企業財務分析
    Gold Fields Ltd - Strategy, SWOT and Corporate Finance Report Summary Gold Fields Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Dentsu, Inc.：企業の戦略・SWOT・財務分析
    Dentsu, Inc. - Strategy, SWOT and Corporate Finance Report Summary Dentsu, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • IXICO Plc (IXI)-製薬・医療分野：企業M&A・提携分析
    Summary IXICO Plc (IXICO), formerly Phytopharm plc is a provider of clinical trial services and technology for the evaluation of imaging endpoints. The company provides clinical trial services for assessing the safety and efficacy of drugs. Its product portfolio includes web-based platform to transf …
  • Cooper Energy Ltd (COE)：企業の財務・戦略的SWOT分析
    Summary Cooper Energy Ltd (CEL) is an oil and gas exploration and production company that offers oil production programs. The company produces, and commercializes crude oil and natural gas products. It conducts exploration for oil and gas through a portfolio of prospective acreage in the Cooper, Otw …
  • Owens & Minor Inc (OMI)-医療機器分野：企業M&A・提携分析
    Summary Owens & Minor Inc (Owens & Minor) is a healthcare services company, which provides supply chain services to healthcare providers and manufacturers of healthcare products. It provides logistics services for disposable medical supplies, devices and implants. Owens & Minor offers medical and su …
  • NN Group NV：企業の戦略・SWOT・財務情報
    NN Group NV - Strategy, SWOT and Corporate Finance Report Summary NN Group NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Valio Ltd：企業の戦略的SWOT分析
    Valio Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆